Actinium Pharmaceuticals to discuss results from Phase 3 trial of Iomab-B

Sandesh Seth, Actinium’s Chairman and CEO, said, "We are honored that Dr. Giralt, who is instrumental in advancing the field of bone marrow transplant, will present the SIERRA data and frame how Iomab-B can address the unmet need for the majority of r/r AML patients who are not transplantable today. We are excited to move ahead with the BLA filing of Iomab-B in 2H:2023 following the highly positive, full results from the SIERRA trial which clearly established Iomab-B’s ability to provide unprecedented access to a BMT to patients who currently not transplantable and to meaningfully improve outcomes. Additionally, we are enthused by the other consequential milestones we intend to achieve in 2023 including moving Actimab-A into late-stage development following our recent CRADA with the NCI, additional data and important studies with Iomab-ACT, the Early Access Program for Iomab-B and progress with our earlier stage solid tumor programs. Our current balance sheet of approximately $100 million is expected to fund operations through 2025 and will allow us to continue to create value from these important milestones and provide clarity on how Actinium could radically alter the treatment of r/r AML with Iomab-B and Actimab-A and dramatically improve outcomes".